Other
Sale of investments
Royalty Pharma Sale of investments increased by 50.0% to $4.32M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 65.7%, from $12.59M to $4.32M. Over 4 years (FY 2021 to FY 2025), Sale of investments shows a downward trend with a -23.7% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityVolatile
First reportedQ1 2018
Last reportedQ1 2026May 6, 2026
How to read this metric
High proceeds may indicate active portfolio rebalancing or a strategy to lock in investment gains.
Detailed definition
Represents the cash inflows from the sale of debt securities classified as available-for-sale. This reflects the company...
Peer comparison
Standard metric for insurance companies with large investment portfolios.
Metric ID:
other_proceeds_from_sale_of_available_for_sale_securities_debtHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.63M | $15.63M | $15.63M | $15.63M | $15.63M | $15.63M | $495.17M | $0.00 | $0.00 | $0.00 | $1.44M | $1.44M | $2.88M | $2.88M | $12.59M | $12.59M | $2.88M | $2.88M | $2.88M | $4.32M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | >999% | -100.0% | — | — | — | +0.0% | +100.0% | +0.0% | +337.0% | +0.0% | -77.1% | +0.0% | +0.0% | +50.0% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | >999% | -100.0% | -100.0% | -100.0% | -99.7% | — | — | — | +774.0% | +774.0% | +0.0% | +0.0% | -77.1% | -65.7% |
Range$0.00 – $495.17M
CAGR-23.7%
Avg YoY Growth+313.4%
Median YoY Growth+0.0%
Current Streak3 quarters growth
Sale of investments at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's sale of investments?
- Royalty Pharma (RPRX) reported sale of investments of $4.32M in Q1 2026.
- How has Royalty Pharma's sale of investments changed year-over-year?
- Royalty Pharma's sale of investments decreased by 65.7% year-over-year, from $12.59M to $4.32M.
- What is the long-term trend for Royalty Pharma's sale of investments?
- Over 4 years (2021 to 2025), Royalty Pharma's sale of investments has grown at a -23.7% compound annual growth rate (CAGR), from $62.50M to $21.23M.
- What does sale of investments mean?
- Cash received from selling debt investments held in the portfolio.